Sanofi (SAN) Stock Forecast & Price Target

Compare

273 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAN Analyst Ratings

Strong Buy

11 Buy

3 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAN Stock 12 Month Forecast

Average Price Target

€103.05

▲(25.48% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €103.05 with a high forecast of €118.96 and a low forecast of €94.96. The average price target represents a 25.48% change from the last price of €82.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"€79","89":"€89","99":"€99","109":"€109","119":"€119"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118.95524380345675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€118.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.046378092,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€103.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.9642702632638,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,89,99,109,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.59,89.07963413872744,91.56926827745488,94.05890241618233,96.54853655490977,99.03817069363721,101.52780483236465,104.0174389710921,106.50707310981954,108.99670724854698,111.48634138727442,113.97597552600186,116.4656096647293,{"y":118.95524380345675,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.59,87.85587523784616,89.12175047569231,90.38762571353847,91.65350095138461,92.91937618923077,94.18525142707692,95.45112666492308,96.71700190276923,97.98287714061539,99.24875237846153,100.51462761630769,101.78050285415384,{"y":103.046378092,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.59,87.23417463563568,87.87834927127136,88.52252390690704,89.1666985425427,89.81087317817838,90.45504781381406,91.09922244944974,91.74339708508542,92.3875717207211,93.03174635635676,93.67592099199244,94.32009562762812,{"y":94.9642702632638,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":87.946,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.785,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.995,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.957,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.716,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.854,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€118.96

Average Price Target€103.05

Lowest Price Target€94.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

€110

Buy

33.95%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Danaher (NYSE: DHR), Novan (NASDAQ: NOVN) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€105

Buy

27.86%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Benjamin Jackson CFA

Jefferies

€100

Buy

21.77%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Cogstate Ltd (Other OTC: COGZF) and Sanofi (Other OTC: SNYNF)

Richard Vosser

J.P. Morgan

€95

Hold

15.68%

Upside

Reiterated

12/15/25

Sachin Jain

Bank of America Securities

€102

Buy

24.21%

Upside

Reiterated

12/15/25

Sanofi: Buy Rating Maintained Amid Attractive Valuation and Long-Term Growth Potential Despite Pipeline Setbacks

Shirley Chen

Barclays

€105

Buy

27.86%

Upside

Reiterated

12/15/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BillionToOne, Inc. Class A (NASDAQ: BLLN), HCA Healthcare (NYSE: HCA) and Sanofi (Other OTC: SNYNF)

James Quigley

Goldman Sachs

€95

Hold

15.68%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Rajesh Kumar

HSBC

€102→€100

Buy

21.77%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Florent Cespedes

Bernstein

€119

Buy

44.91%

Upside

Reiterated

12/05/25

Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)

Luisa Hector

Berenberg Bank

€110

Buy

33.95%

Upside

Reiterated

11/06/25

Berenberg Bank Remains a Buy on Sanofi (SNYNF)

Nicolas Pauillac

Kepler Capital

€95

Hold

15.68%

Upside

Reiterated

10/24/25

Kepler Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/24/25

DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)

David Risinger

Leerink Partners

Buy

―

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (NASDAQ: SOPH) and Sanofi (Other OTC: SNYNF)

Seamus Fernandez

Guggenheim

€104→€101

Buy

22.99%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Sarita Kapila

Morgan Stanley

€100

Buy

21.77%

Upside

Upgraded

09/08/25

Positive Report for Sanofi (SNYNF) from Morgan Stanley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

€110

Buy

33.95%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Danaher (NYSE: DHR), Novan (NASDAQ: NOVN) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€105

Buy

27.86%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Benjamin Jackson CFA

Jefferies

€100

Buy

21.77%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Cogstate Ltd (Other OTC: COGZF) and Sanofi (Other OTC: SNYNF)

Richard Vosser

J.P. Morgan

€95

Hold

15.68%

Upside

Reiterated

12/15/25

Sachin Jain

Bank of America Securities

€102

Buy

24.21%

Upside

Reiterated

12/15/25

Sanofi: Buy Rating Maintained Amid Attractive Valuation and Long-Term Growth Potential Despite Pipeline Setbacks

Shirley Chen

Barclays

€105

Buy

27.86%

Upside

Reiterated

12/15/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BillionToOne, Inc. Class A (NASDAQ: BLLN), HCA Healthcare (NYSE: HCA) and Sanofi (Other OTC: SNYNF)

James Quigley

Goldman Sachs

€95

Hold

15.68%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Rajesh Kumar

HSBC

€102→€100

Buy

21.77%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Florent Cespedes

Bernstein

€119

Buy

44.91%

Upside

Reiterated

12/05/25

Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)

Luisa Hector

Berenberg Bank

€110

Buy

33.95%

Upside

Reiterated

11/06/25

Berenberg Bank Remains a Buy on Sanofi (SNYNF)

Nicolas Pauillac

Kepler Capital

€95

Hold

15.68%

Upside

Reiterated

10/24/25

Kepler Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/24/25

DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)

David Risinger

Leerink Partners

Buy

―

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (NASDAQ: SOPH) and Sanofi (Other OTC: SNYNF)

Seamus Fernandez

Guggenheim

€104→€101

Buy

22.99%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Sarita Kapila

Morgan Stanley

€100

Buy

21.77%

Upside

Upgraded

09/08/25

Positive Report for Sanofi (SNYNF) from Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month

xxx

Success Rate

10/19 ratings generated profit

Average Return

-0.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.63% of your transactions generating a profit, with an average return of -0.23% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+1.13%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +1.13% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

21/34 ratings generated profit

Average Return

+3.03%

reiterated a buy rating 2 months ago

Copying David Risinger's trades and holding each position for 1 Year would result in 61.76% of your transactions generating a profit, with an average return of +3.03% per trade.

2 Years

xxx

Success Rate

15/26 ratings generated profit

Average Return

+5.27%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.69% of your transactions generating a profit, with an average return of +5.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAN has received 31 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. SAN average Analyst price target in the past 3 months is 103.05.

Each month's total comprises the sum of three months' worth of ratings.

SAN Financial Forecast

SAN Earnings Forecast

Next quarter’s earnings estimate for SAN is €1.41 with a range of €1.32 to €1.50. The previous quarter’s EPS was €2.91. SAN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SAN has Performed in-line its overall industry.

SAN Sales Forecast

Next quarter’s sales forecast for SAN is €11.56B with a range of €11.05B to €11.98B. The previous quarter’s sales results were ―. SAN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SAN has Performed in-line its overall industry.

SAN Stock Forecast FAQ

What is FR:SAN’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 103.05.

What is FR:SAN’s upside potential, based on the analysts’ average price target?

Sanofi has 25.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Strong Buy, which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 103.05. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €118.96 ,and the lowest forecast is €94.96. The average share price target represents 25.48% Increase from the current price of €82.12.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of FR:SAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sanofi (SAN) Stock Forecast & Price Target

SAN Analyst Ratings

SAN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SAN Analyst Recommendation Trends

SAN Financial Forecast

SAN Earnings Forecast

SAN Sales Forecast

SAN Stock Forecast FAQ

Detailed List of Analyst Forecasts